April 1, 2008 — An angioplasty balloon coated with a drug that reduces renarrowing of the coronary arteries appears to be more effective than a drug-eluting stent in treating an unwanted build-up of tissue inside a bare-metal coronary stent. After six months, the newly expanded artery remained more widely open within the stent after treatment with the paclitaxel-eluting balloon when compared to a paclitaxel-eluting stent, according to the Paclitaxel-Eluting PTCA-Balloon Catheter in Coronary Artery Disease II-In-Stent Restenosis (PEPCAD II-ISR) study.

April 1, 2008 — Early results of the SPIRIT II study showed that the XIENCE V sstent was superior to the Taxus stent in six-month findings on angiography and trended better on one- year clinical outcomes. Now, a new analysis shows that after two years, the investigational everolimus- coated XIENCE V stent may continue to hold a clinical edge over its paclitaxel-coated competitor.

April 1, 2008 — A large community-based registry of patients treated with drug eluting stents is providing important insight into how long patients with complex coronary artery disease typically stick to their doctors’ orders to take clopidogrel, a drug that prevents unwanted blood clots; why they stop taking the drug; and the long-term consequences of that decision.

April 1, 2008 - Wacom featured its new DTZ-2100 interactive pen at ACC 2008.

The DTZ-2100 is designed for working directly on screen, providing an intuitive way to document conditions, treatments and procedures for planning or educational purposes. Clinicians can annotate over digital medical images, contour directly on CT slices, select specific regions of interest and take measurements of complex objects. The large, high-resolution display reportedly provides image detail and easy viewability.

April 1, 2008 – At ACC 2008, Biomedical Systems showcased its Data Exchange, a proprietary Internet-based application that has been designed for the acquisition, transfer, review and management of Holter data. The application allows for acquire the digital Holter recording from your facility and transmit to Biomedical Systems’ analysis lab, receive completed Holter reports as PDF files within 24 hours of transmitting a recording and allows for online installation on your existing computer including automatic updates as soon as they are released.

April 1, 2008 - Northeast Monitoring showcased its recently-released DR200/HE, a combination 14-day Holter plus 30-day event recorder integrated into a single unit that is designed for deployment to patients in either 'Holter' or 'event' mode, at ACC 2008.

April 1, 2008 – Boston Scientific announced results from an analysis two-year data from more than 7,000 patients in the TAXUS ARRIVE Registry program, a study designed to evaluate the safety performance of the TAXUS Express Paclitaxel-Eluting Coronary Stent System in patients treated in “real-world” practice.

Outcomes through the two-year period in the simple-use (single vessel/stent) patient group confirmed the favorable results seen in similar patient enrolled in previous TAXUS randomized clinical trials (the clinical trial cohort).

April 1, 2008 - Physio-Control featured its LifePak 12 Defibrillator/Monitor, a multi-parameter device combining semi-automated and manual defibrillation with capnography, external pacing, 12-lead electrocardiology, at ACC 2008.

The unit is available with ADAPTIV biphasic technology and comes with a choice of standard, pediatric and/or sterlizable internal and external paddles. It’s compatible with QUIK-COMBO pacing/defibrillation/ECG electrodes.

April 1, 2008 – A new high-performance bandage made from the same blood-stopping technology the U.S. Army uses in Afghanistan and Iraq was featured at ACC 2008.

When in direct contact with blood and pressure is applied — including the Femoral Artery — the KytoStat Bandage stops bleeding while sealing and protecting the wound.

April 1, 2008 – Boston Scientific welcomed results from Abbott’s prospective, randomized, single blind, two-year SPIRIT II Trial, comparing the safety and efficacy of the XIENCE V (PROMUS) Everolimus-Eluting Coronary Stent and Boston Scientific’s TAXUS Express Paclitaxel Eluting Coronary Stent System in 300 patients in Europe.

The PROMUS Stent is a private-label XIENCE V manufactured by Abbott and distributed by Boston Scientific.

Subscribe Now